POST-TEST

Multiple Myeloma Update

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. **Results of the Phase III MAIA trial evaluating lenalidomide/dexamethasone with or without daratumumab for patients with previously untreated MM who are not eligible for ASCT demonstrated a statistically significant improvement in _____ with the addition of daratumumab in the intent-to-treat population.**
   a. Overall survival
   b. Progression-free survival
   c. Both a and b
   d. Neither a nor b

2. **Results of the Phase III CASSIOPEIA study evaluating bortezomib/thalidomide/dexamethasone with or without daratumumab for transplant-eligible patients with newly diagnosed MM demonstrated a significant improvement in _____ with the addition of daratumumab.**
   a. MRD negativity rate
   b. Overall response rate
   c. Progression-free survival
   d. Both b and c
   e. Both a and b
   f. Both a and c
   g. All of the above

3. **CAR T-cell therapy platforms in MM are engineered against BCMA because it is ubiquitously expressed at high levels on MM cells but not on other tissue except normal plasma cells.**
   a. True
   b. False

4. **Emerging data evaluating the novel agent melflufen for patients with R/R MM demonstrate _____.**
   a. Durable activity when used in combination with dexamethasone
   b. Synergistic activity in combination with dexamethasone and either bortezomib or daratumumab
   c. Improved tolerability in comparison to standard melphalan
   d. All of the above
   e. Both a and c
   f. Both b and c

5. **Which of the following adverse events is commonly associated with investigational anti-BCMA CAR T-cell therapy platforms in the management of R/R MM?**
   a. Cytokine release syndrome
   b. Neurologic toxicity
   c. Both a and b

6. **Results of the Phase III BELLINI trial investigating the efficacy and safety of bortezomib and dexamethasone with or without the Bcl-2 inhibitor venetoclax for patients with R/R MM demonstrated a statistically significant improvement in overall survival with the addition of venetoclax in the overall study population.**
   a. True
   b. False

7. **Which of the following drug categories reflects the mechanism of action of the recently FDA-approved agent selinexor?**
   a. Bispecific T-cell engager
   b. Proteasome inhibitor
   c. XPO1 inhibitor

8. **Data from the Phase III COLUMBA trial evaluating subcutaneous versus intravenous administration of daratumumab for patients with R/R MM reported _____ rates of infusion-related reactions with the subcutaneous administration.**
   a. Equivalent
   b. Significantly higher
   c. Significantly lower

9. **BRAF mutations _____ in patients with MM.**
   a. Do not occur
   b. Occur at a rate of approximately 4%
   c. Occur at a rate of approximately 30%

10. **Which of the following statements is true regarding the FDA-approved agent ixazomib for MM?**
    a. It is an oral proteasome inhibitor
    b. It demonstrates activity in the R/R setting
    c. It has not demonstrated efficacy for newly diagnosed disease
    d. All of the above
    e. Both a and b
    f. Both b and c

QIDs 2328, 2329